AstraZeneca, Tesaro and Clovis need to slash the cost of PARP meds, watchdog says
admin 2nd October 2017 Uncategorised 0Ovarian cancer patients who respond to chemo have some new treatments designed to keep their disease at bay. But a cost-effectiveness watchdog isn’t convinced those meds are worth their price in that setting, and only one hit a cost target in recurrent disease.
More: AstraZeneca, Tesaro and Clovis need to slash the cost of PARP meds, watchdog says
Source: fierce